{"id":"irbesartan-amlodipine-and-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Dizziness"},{"rate":"3-8","effect":"Fatigue"},{"rate":"5-10","effect":"Headache"},{"rate":"2-5","effect":"Hyperuricemia"},{"rate":"2-5","effect":"Hypokalemia"},{"rate":"1-3","effect":"Cough"},{"rate":"2-5","effect":"Peripheral edema"}]},"_chembl":{"chemblId":"CHEMBL1200402","moleculeType":"Small molecule","molecularWeight":"567.06"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Irbesartan is an angiotensin II receptor blocker (ARB) that prevents vasoconstriction and aldosterone release. Amlodipine is a calcium channel blocker that relaxes vascular smooth muscle. Hydrochlorothiazide is a thiazide diuretic that reduces blood volume and sodium reabsorption. Together, these agents provide synergistic blood pressure reduction through distinct pathways.","oneSentence":"This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: blocking angiotensin II receptors, inhibiting calcium influx into vascular smooth muscle, and promoting sodium and water excretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:13.865Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (essential hypertension in patients requiring combination therapy)"}]},"trialDetails":[{"nctId":"NCT06790927","phase":"NA","title":"Standardized Antihypertensive Treatment Protocol","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2025-02-24","conditions":"Hypertension","enrollment":400},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT00535925","phase":"PHASE4","title":"Nephropathy In Type 2 Diabetes and Cardio-renal Events","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":"Diabetic Nephropathy","enrollment":850},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT00219115","phase":"PHASE3","title":"A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-01","conditions":"Hypertension","enrollment":493},{"nctId":"NCT00224549","phase":"PHASE4","title":"PHARES Study: Management of Resistant Hypertension","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2005-04","conditions":"Hypertension","enrollment":180},{"nctId":"NCT00264212","phase":"PHASE4","title":"AMISH : Aprovel for Management of Isolated Systolic Hypertension","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-08","conditions":"Hypertension","enrollment":436}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"irbesartan, amlodipine and hydrochlorothiazide","genericName":"irbesartan, amlodipine and hydrochlorothiazide","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: blocking angiotensin II receptors, inhibiting calcium influx into vascular smooth muscle, and promoting sodium and water excretion. Used for Hypertension (essential hypertension in patients requiring combination therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}